
  
    
      
        Background_NNP
        Tuberculosis_NNP is_VBZ estimated_VBN to_TO cause_VB at_IN least_JJS three_CD
        million_CD deaths_NNS per_IN year_NN worldwide_NN [_NN 1_CD ]_NN and_CC also_RB accounts_VBZ
        for_IN more_JJR than_IN one-quarter_NN of_IN all_DT preventable_JJ adult_NN deaths_NNS
        in_IN developing_VBG countries_NNS [_NN 2_CD ]_NN ._. Infection_NNP with_IN the_DT human_JJ
        immuno-deficiency_JJ virus_NN (_( HIV_NNP )_) is_VBZ thought_VBN to_TO be_VB the_DT single_JJ
        most_RBS important_JJ factor_NN that_WDT has_VBZ contributed_VBN to_TO the_DT increased_VBN
        incidence_NN of_IN tuberculosis_NNS globally_RB in_IN the_DT last_JJ decade_NN [_NN 2_CD ]_NN
        ._. Tuberculosis_NNP is_VBZ now_RB the_DT leading_VBG cause_NN of_IN death_NN among_IN
        HIV-infected_NNP individuals_NNS worldwide_NN and_CC accounts_NNS for_IN at_IN
        least_JJS 40_CD %_NN of_IN deaths_NNS among_IN HIV-infected_NNP persons_NNS in_IN Africa_NNP [_NN
        3_CD ]_NN ._. Furthermore_RB ,_, tuberculosis_NNS kills_VBZ more_JJR women_NNS than_IN any_DT
        other_JJ infectious_JJ disease_NN ,_, including_VBG malaria_NN and_CC AIDS_NNP [_NN 4_CD ]_NN
        ._.
        Reports_NNS have_VBP suggested_VBN that_IN responses_NNS to_TO tuberculosis_NNS
        differ_VBP between_IN men_NNS and_CC women_NNS ,_, and_CC that_IN barriers_NNS to_TO early_JJ
        detection_NN and_CC treatment_NN of_IN tuberculosis_NNS may_MD be_VB greater_JJR for_IN
        women_NNS than_IN for_IN men_NNS [_NN 5_CD ]_NN ._. A_DT 10_CD -_: year_NN study_NN performed_VBN among_IN
        Ethiopian_JJ Jews_NNPS who_WP immigrated_VBD to_TO Israel_NNP found_VBD that_IN women_NNS
        had_VBD an_DT incidence_NN rate_NN of_IN tuberculosis_NNS that_WDT was_VBD twice_RB that_IN
        of_IN men_NNS (_( 120_CD versus_CC 69_CD cases_NNS per_IN 100_CD ,_, 000_CD population_NN per_IN
        year_NN )_) [_NN 6_CD ]_NN ._. In_IN addition_NN ,_, studies_NNS have_VBP suggested_VBN that_DT
        progression_NN from_IN tuberculosis_NNS infection_NN to_TO disease_NN may_MD be_VB
        faster_JJR in_IN women_NNS of_IN reproductive_JJ age_NN than_IN men_NNS of_IN the_DT same_JJ
        age_NN [_NN 7_CD 8_CD ]_NN ._. Nonetheless_RB ,_, there_EX is_VBZ an_DT estimated_VBN 2_CD :_: 1_CD male_JJ
        to_TO female_JJ ratio_NN in_IN the_DT number_NN of_IN tuberculosis_NNS cases_NNS
        notified_VBN to_TO public_JJ health_NN authorities_NNS [_NN 9_CD ]_NN ,_, indicating_VBG
        that_IN any_DT increase_NN in_IN the_DT risk_NN of_IN development_NN of_IN
        tuberculosis_NNS that_IN reproductive_JJ stress_NN may_MD confer_VB upon_IN women_NNS
        is_VBZ transient_JJ ._. Despite_IN this_DT disparity_NN in_IN case_NN notifications_NNS ,_,
        mortality_NN from_IN tuberculosis_NNS is_VBZ similar_JJ among_IN young_JJ males_NNS
        and_CC females_NNS in_IN Africa_NNP [_NN 10_CD ]_NN ._.
        The_DT literature_NN lacks_VBZ information_NN on_IN the_DT relationship_NN
        between_IN gender_NN ,_, tuberculosis_NNS ,_, HIV-infection_NNP ,_, and_CC the_DT
        outcome_NN of_IN tuberculosis_NNS in_IN Africa_NNP ._. Studies_NNS that_WDT have_VBP
        examined_VBN gender_NN relationships_NNS in_IN tuberculosis_NNS patients_NNS
        found_VBD a_DT similar_JJ proportion_NN of_IN HIV_NNP infection_NN among_IN males_NNS and_CC
        females_NNS in_IN Tanzania_NNP [_NN 11_CD ]_NN ,_, Zambia_NNP [_NN 12_CD ]_NN and_CC Kenya_NNP [_NN 13_CD ]_NN
        ._. Among_IN younger_JJR age_NN groups_NNS ,_, female_JJ tuberculosis_NNS patients_NNS
        were_VBD more_RBR likely_JJ to_TO be_VB HIV-infected_NNP than_IN males_NNS whereas_IN the_DT
        opposite_NN was_VBD found_VBN in_IN older_JJR age_NN groups_NNS ._.
        In_IN 1992_CD ,_, almost_RB 1_CD ._. 5_CD million_CD (_( 8_CD ._. 8_CD %_NN )_) of_IN the_DT 17_CD million_CD
        people_NNS in_IN Uganda_NNP were_VBD estimated_VBN to_TO have_VB been_VBN infected_VBN with_IN
        HIV_NNP ._. Of_IN these_DT ,_, 50_CD %_NN were_VBD estimated_VBN to_TO have_VB tuberculosis_NNS
        co-infection_JJ [_NN 14_CD ]_NN ._. The_DT total_JJ number_NN of_IN notifications_NNS of_IN
        tuberculosis_NNS cases_NNS of_IN all_DT forms_NNS has_VBZ been_VBN steadily_RB rising_VBG in_IN
        Uganda_NNP ,_, from_IN 14_CD ,_, 740_CD in_IN 1990_CD to_TO 27_CD ,_, 196_CD in_IN 1996_CD (_( an_DT increase_NN
        of_IN over_IN 90_CD %_NN )_) ,_, even_RB with_IN an_DT estimated_VBN case_NN detection_NN rate_NN of_IN
        about_IN 44_CD %_NN [_NN 15_CD ]_NN ._.
        This_DT report_NN describes_VBZ an_DT investigation_NN of_IN the_DT
        relationship_NN between_IN gender_NN and_CC the_DT baseline_NN presentation_NN
        and_CC one-year_JJ outcome_NN in_IN a_DT cohort_NN of_IN HIV-infected_NNP pulmonary_JJ
        tuberculosis_NNS patients_NNS in_IN on_IN tuberculosis_NNS treatment_NN in_IN
        Uganda_NNP ._.
      
      
        Methods_NNP
        
          Study_NN population_NN
          Between_IN March_NNP 1993_CD and_CC March_NNP 1995_CD ,_, 18_CD to_TO 50_CD year_NN old_JJ
          HIV-infected_NNP patients_NNS with_IN initial_JJ episodes_NNS of_IN sputum_NN
          acid-fast_JJ bacilli_NN (_( AFB_NNP )_) smear-positive_JJ ,_, culture-confirmed_JJ
          pulmonary_JJ tuberculosis_NNS were_VBD enrolled_VBN at_IN the_DT National_NNP
          Tuberculosis_NNP Treatment_NNP Center_NNP ,_, Kampala_NNP ,_, Uganda_NNP in_IN a_DT
          prospective_JJ cohort_NN study_NN ._. All_DT patients_NNS received_VBD
          anti-tuberculosis_JJ treatment_NN consisting_VBG of_IN two_CD months_NNS of_IN
          daily_JJ self-administered_JJ isoniazid_NN (_( INH_NNP )_) ,_, rifampicin_NN ,_,
          ethambutol_NN ,_, and_CC pyrazinamide_NN ,_, followed_VBN by_IN six_CD months_NNS of_IN
          daily_JJ INH_NNP and_CC rifampicin_NN ,_, which_WDT was_VBD the_DT recommended_VBD first_JJ
          line_NN treatment_NN by_IN the_DT World_NNP Health_NNP Organization_NNP
          (_( WHO_WP )_) ._.
          Other_JJ inclusion_NN criteria_NNS included_VBD residence_NN within_IN 20_CD
          kilometers_NNS of_IN the_DT Tuberculosis_NNP Treatment_NNP Center_NNP ,_,
          ambulatory_JJ performance_NN status_NN (_( assessed_VBN by_IN a_DT Karnofsky_NNP
          performance_NN score_NN of_IN greater_JJR than_IN 50_CD %_NN )_) [_NN 16_CD ]_NN ,_, and_CC
          ability_NN to_TO provide_VB informed_VBN consent_NN ._. Exclusion_NNP criteria_NNS
          included_VBD previous_JJ tuberculosis_NNS or_CC tuberculosis_NNS treatment_NN ,_,
          serious_JJ co-morbidity_JJ such_JJ as_IN diabetes_NN mellitus_JJ or_CC
          hypertension_NN ,_, steroid_NN or_CC antiretroviral_NN use_NN (_( since_IN there_EX
          was_VBD no_DT consistent_JJ policy_NN in_IN Uganda_NNP on_IN the_DT use_NN of_IN
          antiretroviral_NN treatment_NN between_IN 1992_CD and_CC 1995_CD )_) ,_,
          pregnancy_NN ,_, and_CC WHO_WP clinical_JJ stage_NN IV_NNP AIDS_NNP [_NN 17_CD ]_NN ._.
          At_IN baseline_NN and_CC monthly_JJ follow-up_JJ visits_NNS ,_, patients_NNS had_VBD
          a_DT full_JJ medical_JJ history_NN and_CC physical_JJ examination_NN ,_, a_DT
          complete_JJ blood_NN count_NN (_( Coulter_NNP Electronics_NNP ,_, Hialeah_NNP ,_,
          Florida_NNP ,_, USA_NNP )_) ,_, sputum_NN AFB_NNP microscopy_NN and_CC culture_NN ,_, chest_NN
          radiography_NN ,_, and_CC serum_NN β_NN 
          2_CD -_: microglobulin_NN measurement_NN (_( β_NN 
          2_CD -_: microglobulin_NN enzyme_NN immunoassay_NN
          (_( EIA_NNP )_) ;_: Coulter_NNP ,_, Miami_NNP ,_, Florida_NNP ,_, USA_NNP )_) ._. The_DT upper_JJ limit_NN of_IN
          normal_JJ for_IN serum_NN β_NN 
          2_CD microglobulin_NN for_IN healthy_JJ
          HIV-seronegative_NNP Ugandan_NNP adults_NNS is_VBZ 3_CD ._. 5_CD mg_NN /_NN L_NNP [_NN 18_CD ]_NN ._.
          HIV-infection_NNP was_VBD determined_VBN by_IN HIV-_NNP 1_CD EIA_NNP (_( Recombigen_NNP
          HIV-_NNP 1_CD env_NN +_NN gag_NN EIA_NNP ;_: Cambridge_NNP Bioscience_NNP ,_, Worcester_NNP ,_,
          Massachusetts_NNP ,_, USA_NNP )_) ._. Consistency_NNP of_IN the_DT HIV-EIA_NNP results_NNS
          was_VBD maintained_VBN by_IN confirmatory_NN testing_NN according_VBG to_TO a_DT
          protocol_NN that_WDT was_VBD in_IN use_NN at_IN the_DT study_NN center_NN -_: one_CD of_IN 10_CD
          HIV-_NNP 1_CD EIA_NNP positive_JJ and_CC one_CD of_IN 25_CD HIV-_NNP 1_CD negative_JJ sera_NN
          underwent_VBD confirmatory_NN testing_NN by_IN HIV-_NNP 1_CD Western_NNP
          immunoblotting_VBG (_( BioRad_NNP Novapath_NNP ,_, Hercules_NNP ,_, California_NNP ,_,
          USA_NNP )_) ._. All_DT study_NN subjects_NNS received_VBD pre-_NN and_CC post-_NN HIV_NNP test_NN
          counseling_NN from_IN trained_VBN counselors_NNS and_CC received_VBD the_DT
          standard_JJ management_NN for_IN HIV-_NNP 1_CD infection_NN available_JJ in_IN
          Uganda_NNP at_IN the_DT time_NN of_IN the_DT study_NN ,_, which_WDT included_VBD treatment_NN
          of_IN oral_JJ thrush_NN ,_, herpes_NNS simplex_NN ,_, herpes_NNS zoster_NN ,_, and_CC
          recurrent_JJ bacterial_JJ infections_NNS ._. Antiretroviral_NNP therapy_NN
          was_VBD not_RB the_DT standard_NN of_IN practice_NN in_IN Uganda_NNP during_IN the_DT
          study_NN and_CC was_VBD not_RB given_VBN to_TO the_DT study_NN subjects_NNS ._.
          Peripheral_NNP blood_NN CD_NNP 4_CD +_NN lymphocyte_NN counts_NNS were_VBD measured_VBN
          by_IN flow_NN cytometry_NN (_( Becton-_NNP Dickinson_NNP ,_, Santa_NNP Rosa_NNP ,_, CA_NNP )_) at_IN
          baseline_NN and_CC one_CD ,_, two_CD ,_, six_CD ,_, nine_CD ,_, and_CC 12_CD months_NNS after_IN the_DT
          onset_NN of_IN anti-_NN TB_NN chemotherapy_NN ._. Tuberculin_NNP skin_NN tests_NNS were_VBD
          performed_VBN at_IN baseline_NN and_CC one_CD year_NN follow-up_JJ by_IN the_DT
          Mantoux_NNP method_NN using_VBG purified_JJ protein_NN derivative_JJ (_( 5_CD
          tuberculin_NN units_NNS of_IN Tubersol_NNP PPD_NNP ,_, Connaught_NNP ,_, Swiftwater_NNP ,_,
          Pennsylvania_NNP ,_, USA_NNP )_) [_NN 19_CD ]_NN ._. Home_NNP health-visitors_JJ
          contacted_VBD patients_NNS who_WP defaulted_VBD on_IN clinic_NN appointments_NNS ._.
          The_DT study_NN protocol_NN was_VBD reviewed_VBN and_CC approved_VBN by_IN the_DT
          Ugandan_NNP National_NNP AIDS_NNP Research_NNP Subcommittee_NNP and_CC the_DT
          institutional_JJ review_NN boards_NNS of_IN Case_NNP Western_NNP Reserve_NNP
          University_NNP and_CC University_NNP Hospitals_NNPS of_IN Cleveland_NNP ._. All_DT
          patients_NNS gave_VBD informed_VBN consent_NN for_IN study_NN
          participation_NN ._.
        
        
          Statistical_NNP analyses_NNS
          We_PRP investigated_VBD the_DT influence_NN of_IN gender_NN on_IN the_DT
          likelihood_NN that_IN a_DT study_NN patient_NN achieved_VBD a_DT favorable_JJ
          outcome_NN (_( i_NNP ._. e_SYM ._. ,_, alive_JJ and_CC cured_VBN of_IN tuberculosis_NNS )_) or_CC an_DT
          unfavorable_JJ outcome_NN (_( i_NNP ._. e_SYM ._. ,_, dead_JJ or_CC not_RB cured_VBN of_IN
          tuberculosis_NNS )_) after_IN one-year_JJ from_IN the_DT initiation_NN of_IN
          anti-tuberculosis_JJ treatment_NN ._. Vital_NNP status_NN was_VBD determined_VBN
          through_IN interviews_NNS of_IN family_NN members_NNS ._. Study_NN subjects_NNS who_WP
          were_VBD acid-fast_JJ bacilli_NN sputum_NN smear_NN and_CC culture_NN negative_JJ
          at_IN the_DT one-year_JJ follow-up_JJ sputum_NN examination_NN were_VBD
          considered_VBN cured_VBN ._. Only_RB subjects_VBZ whose_WP$ status_NN could_MD be_VB
          assigned_VBN into_IN either_DT of_IN the_DT two_CD outcome_NN groups_NNS were_VBD
          included_VBN in_IN the_DT analysis_NN ._. We_PRP evaluated_VBD the_DT bivariate_NN
          relationships_NNS between_IN gender_NN and_CC outcome_NN with_IN selected_VBN
          baseline_NN covariates_NNS ,_, and_CC constructed_VBN a_DT time-series_JJ
          repeated_VBN measures_NNS regression_NN model_NN [_NN 20_CD 21_CD ]_NN to_TO describe_VB
          the_DT influence_NN of_IN gender_NN on_IN the_DT outcome_NN using_VBG data_NNS at_IN
          baseline_NN and_CC two_CD ,_, six_CD ,_, nine_CD and_CC 12_CD months_NNS ._. We_PRP chose_VBD the_DT
          time-series_JJ model_NN because_IN it_PRP accounts_VBZ for_IN the_DT variations_NNS
          of_IN covariates_NNS within_IN the_DT study_NN patients_NNS with_IN time_NN ._. A_DT
          proportional-hazards_JJ regression_NN model_NN was_VBD used_VBN to_TO assess_VB
          the_DT influence_NN of_IN gender_NN on_IN one-year_JJ survival_NN ._. All_DT
          analyses_NNS were_VBD performed_VBN using_VBG the_DT SAS_NNP /_NN STAT_NNP ®_NN (_( version_NN
          6_CD ._. 12_CD ,_, SAS_NNP Institute_NNP ,_, Cary_NNP ,_, North_NNP Carolina_NNP ,_, USA_NNP )_)
          module_NN ._.
        
      
      
        Results_NNS
        Of_IN 251_CD HIV-infected_NNP patients_NNS with_IN pulmonary_JJ tuberculosis_NNS
        who_WP were_VBD enrolled_VBN into_IN the_DT cohort_NN study_NN ,_, 214_CD (_( 86_CD %_NN )_) whose_WP$
        outcome_NN status_NN was_VBD known_VBN as_IN either_DT favorable_JJ (_( i_NNP ._. e_SYM ._. ,_, alive_JJ
        and_CC cured_VBN of_IN tuberculosis_NNS )_) or_CC unfavorable_JJ (_( i_NNP ._. e_SYM ._. ,_, dead_JJ or_CC
        not_RB cured_VBN of_IN tuberculosis_NNS )_) after_IN one-year_JJ of_IN initiation_NN of_IN
        anti-tuberculosis_JJ treatment_NN formed_VBD the_DT sample_NN for_IN this_DT
        analysis_NN ._. The_DT majority_NN of_IN patients_NNS whose_WP$ status_NN could_MD not_RB
        be_VB determined_VBN had_VBN withdrawn_VBN from_IN the_DT study_NN before_IN
        completion_NN of_IN treatment_NN ._.
        Of_IN the_DT 214_CD patients_NNS ,_, 105_CD (_( 49_CD %_NN )_) were_VBD male_JJ and_CC 109_CD (_( 52_CD %_NN )_)
        were_VBD female_JJ (_( table_NN 1_LS )_) ._. At_IN baseline_NN ,_, male_JJ patients_NNS were_VBD
        significantly_RB older_JJR and_CC had_VBD higher_JJR body_NN mass_NN indices_NNS (_( BMI_NNP )_)
        than_IN female_JJ patients_NNS ._. Both_DT male_JJ and_CC female_JJ patients_NNS had_VBD
        similar_JJ educational_JJ levels_NNS and_CC marital_JJ status_NN ._. There_EX was_VBD no_DT
        statistically_RB significant_JJ difference_NN between_IN males_NNS and_CC
        females_NNS in_IN the_DT frequency_NN and_CC previous_JJ duration_NN of_IN symptoms_NNS
        of_IN tuberculosis_NNS (_( cough_NN ,_, fevers_NNS ,_, hemoptysis_NNS and_CC sweats_NNS )_) and_CC
        other_JJ HIV-infection-associated_NNP conditions_NNS (_( herpes_NNS zoster_NN ,_,
        diarrhea_NN ,_, genital_JJ ulcers_NNS and_CC thrush_NN )_) ,_, and_CC Karnofsky_NNP
        performance_NN scores_NNS at_IN baseline_NN ._. However_RB ,_, female_JJ patients_NNS
        had_VBD significantly_RB higher_JJR mean_NN serum_NN β_NN 
        2_CD -_: microglobulin_NN levels_NNS ,_, while_IN male_JJ
        patients_NNS had_VBD significantly_RB higher_JJR hemoglobin_NN levels_NNS ._. There_EX
        was_VBD no_DT difference_NN in_IN baseline_NN CD_NNP 4_CD +_NN cell_NN counts_VBZ and_CC PPD_NNP skin_NN
        test_NN reactivity_NN between_IN males_NNS and_CC females_NNS ._.
        At_IN one-year_JJ from_IN the_DT time_NN of_IN initiation_NN of_IN
        anti-tuberculosis_JJ treatment_NN ,_, 169_CD (_( 79_CD %_NN )_) of_IN the_DT 214_CD study_NN
        patients_NNS had_VBD experienced_VBN a_DT favorable_JJ outcome_NN (_( table_NN 2_LS )_) ._. In_IN
        a_DT comparison_NN of_IN baseline_NN characteristics_NNS ,_, patients_NNS who_WP
        developed_VBD a_DT favorable_JJ outcome_NN were_VBD similar_JJ in_IN age_NN to_TO those_DT
        with_IN an_DT unfavorable_JJ outcome_NN but_CC they_PRP had_VBD higher_JJR BMI_NNP and_CC had_VBD
        more_JJR years_NNS of_IN education_NN ._. Both_DT groups_NNS had_VBD similar_JJ
        tuberculosis_NNS and_CC HIV-infection-associated_NNP symptoms_NNS though_IN
        the_DT subjects_NNS with_IN an_DT unfavorable_JJ outcome_NN were_VBD more_RBR likely_JJ
        to_TO have_VB presented_VBN with_IN a_DT past_JJ history_NN of_IN fever_NN ,_, diarrhea_NN ,_,
        and_CC thrush_NN ._. In_IN addition_NN ,_, patients_NNS with_IN a_DT favorable_JJ outcome_NN
        had_VBD larger_JJR PPD_NNP skin_NN test_NN reactions_NNS ,_, higher_JJR absolute_JJ CD_NNP 4_CD +_NN
        cell_NN counts_VBZ ,_, lower_JJR serum_NN β_NN 
        2_CD microglobulin_NN levels_NNS ,_, and_CC were_VBD more_RBR
        likely_JJ to_TO have_VB fibrotic_JJ changes_NNS on_IN their_PRP$ initial_JJ chest_NN
        x-ray_JJ ,_, than_IN subjects_NNS with_IN an_DT unfavorable_JJ outcome_NN ._.
        Furthermore_RB ,_, patients_NNS who_WP experienced_VBD a_DT favorable_JJ outcome_NN
        had_VBD significantly_RB higher_JJR baseline_NN Karnofsky_NNP performance_NN
        status_NN than_IN those_DT with_IN an_DT unfavorable_JJ outcome_NN ._.
        In_IN an_DT unadjusted_JJ comparison_NN between_IN gender_NN and_CC outcome_NN ,_,
        87_CD (_( 80_CD %_NN )_) of_IN the_DT 109_CD female_JJ patients_NNS compared_VBN to_TO 82_CD (_( 78_CD %_NN )_) of_IN
        the_DT 105_CD male_JJ patients_NNS had_VBD experienced_VBN a_DT favorable_JJ outcome_NN
        at_IN one-year_JJ (_( relative_JJ risk_NN 1_CD ._. 0_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 9_CD -_: 1_CD ._. 2_LS )_) ._. From_IN the_DT
        repeated_VBN measures_NNS model_NN ,_, female_JJ subjects_NNS were_VBD more_RBR likely_JJ
        to_TO have_VB a_DT favorable_JJ outcome_NN at_IN one-year_JJ although_IN the_DT effect_NN
        was_VBD not_RB statistically_RB significant_JJ (_( OR_NNP 1_CD ._. 1_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 5_CD -_: 2_CD ._. 1_LS )_) ,_,
        after_IN controlling_VBG for_IN CD_NNP 4_CD +_NN cell_NN count_NN ,_, serum_NN β_NN 
        2_CD microglobulin_NN ,_, hemoglobin_NN ,_, BMI_NNP ,_,
        symptoms_NNS and_CC radiology_NN (_( table_NN 3_LS )_) ._. Additionally_RB increasing_VBG
        CD_NNP 4_CD +_NN cell_NN count_NN (_( OR_NNP 1_CD ._. 002_CD ,_, p_NN <_NN 0_CD ._. 005_CD )_) ,_, increasing_VBG
        hemoglobin_NN (_( OR_NNP 1_CD ._. 1_CD ,_, p_NN =_SYM 0_CD ._. 07_CD )_) ,_, increasing_VBG BMI_NNP (_( OR_NNP 1_CD ._. 1_CD ,_, p_NN =_SYM
        0_CD ._. 06_CD )_) and_CC decreasing_VBG serum_NN β_NN 
        2_CD microglobulin_NN (_( OR_NNP 0_CD ._. 97_CD ,_, p_NN =_SYM 0_CD ._. 07_CD )_) were_VBD
        associated_VBN with_IN a_DT favorable_JJ outcome_NN ._.
        Among_IN the_DT 45_CD subjects_NNS with_IN an_DT unfavorable_JJ outcome_NN 1_CD -_: year_NN
        after_IN the_DT beginning_NN of_IN anti-_NN TB_NN treatment_NN ,_, 38_CD had_VBD died_VBN ._. Of_IN
        the_DT 38_CD dead_JJ patients_NNS ,_, 18_CD (_( 47_CD %_NN )_) were_VBD female_JJ and_CC 20_CD (_( 53_CD %_NN )_)
        were_VBD male_JJ ._. The_DT majority_NN of_IN the_DT patients_NNS died_VBD with_IN the_DT first_JJ
        two_CD months_NNS of_IN TB_NN treatment_NN and_CC we_PRP did_VBD not_RB conduct_VB
        autopsies_NNS ,_, additionally_RB the_DT majority_NN of_IN the_DT patients_NNS in_IN the_DT
        study_NN were_VBD sputum_NN culture_NN negative_JJ at_IN 2_CD months_NNS of_IN
        treatment_NN ._. Because_IN of_IN this_DT difference_NN we_PRP created_VBD a_DT
        proportional-hazards_JJ model_NN to_TO investigate_VB the_DT influence_NN of_IN
        gender_NN on_IN survival_NN ,_, controlling_VBG for_IN baseline_NN presentation_NN
        of_IN fever_NN ,_, diarrhea_NN ,_, serum_NN β_NN 
        2_CD microglobulin_NN ,_, CD_NNP 4_CD +_NN cell_NN count_NN ,_,
        hemoglobin_NN ,_, BMI_NNP ,_, cavitary_JJ disease_NN ,_, and_CC extent_NN of_IN disease_NN on_IN
        chest_NN x-ray_JJ ._. Female_NNP patients_NNS were_VBD less_RBR likely_JJ to_TO have_VB died_VBN
        than_IN male_JJ patients_NNS (_( relative_JJ hazard_NN [_NN RH_NNP ]_NN for_IN death_NN 0_CD ._. 60_CD
        [_NN 95_CD %_NN CI_NNP 0_CD ._. 30_CD -_: 1_CD ._. 21_CD ]_NN )_) but_CC this_DT protective_JJ effect_NN was_VBD not_RB
        statistically_RB significant_JJ ._. Higher_JJR baseline_NN CD_NNP 4_CD +_NN cell_NN count_NN
        (_( RH_NNP 0_CD ._. 995_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 992_CD -_: 0_CD ._. 997_CD )_) ,_, hemoglobin_NN (_( RH_NNP 0_CD ._. 81_CD ,_, 95_CD %_NN CI_NNP
        0_CD ._. 68_CD -_: 0_CD ._. 96_CD )_) ,_, and_CC lesser_JJR extent_NN of_IN disease_NN on_IN chest_NN x-ray_JJ (_( RH_NNP
        0_CD ._. 52_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 28_CD -_: 0_CD ._. 98_CD )_) were_VBD each_DT significantly_RB associated_VBN
        with_IN better_RB survival_NN ._. Baseline_NNP serum_NN β_NN 
        2_CD microglobulin_NN levels_NNS had_VBD no_DT effect_NN on_IN
        survival_NN (_( RH_NNP 1_CD ._. 03_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 93_CD -_: 1_CD ._. 13_CD )_) ._.
      
      
        Discussion_NNP
        We_PRP identified_VBD differences_NNS in_IN the_DT presentation_NN of_IN
        HIV-associated_NNP tuberculosis_NNS between_IN men_NNS and_CC women_NNS in_IN
        Uganda_NNP ;_: however_RB ,_, there_EX were_VBD no_DT differences_NNS in_IN outcomes_NNS or_CC
        survival_NN at_IN one_CD year_NN ._. HIV-infected_NNP women_NNS with_IN pulmonary_JJ
        tuberculosis_NNS were_VBD younger_JJR ,_, had_VBD lower_JJR body_NN mass_NN indices_NNS ,_, and_CC
        were_VBD more_RBR anemic_JJ than_IN men_NNS at_IN the_DT time_NN of_IN presentation_NN ._. This_DT
        is_VBZ consistent_JJ with_IN observations_NNS in_IN other_JJ settings_NNS where_WRB
        tuberculosis_NNS has_VBZ been_VBN shown_VBN to_TO occur_VB more_JJR among_IN younger_JJR
        females_NNS than_IN males_NNS ,_, and_CC in_IN persons_NNS of_IN lower_JJR body_NN mass_NN
        indices_NNS [_NN 22_CD ]_NN ._. However_RB ,_, in_IN our_PRP$ study_NN cohort_NN ,_, female_JJ
        patients_NNS had_VBD higher_JJR serum_NN β_NN 
        2_CD microglobulin_NN levels_NNS at_IN the_DT time_NN of_IN
        diagnosis_NN with_IN tuberculosis_NNS ,_, suggesting_VBG a_DT possibly_RB higher_JJR
        HIV_NNP burden_NN [_NN 23_CD 24_CD ]_NN ,_, than_IN male_JJ patients_NNS despite_IN
        comparable_JJ CD_NNP 4_CD lymphocyte_NN counts_NNS ._. In_IN spite_NN of_IN their_PRP$
        comparative_JJ disadvantage_NN at_IN presentation_NN ,_, female_JJ patients_NNS
        had_VBD a_DT similar_JJ likelihood_NN of_IN a_DT favorable_JJ one-year_JJ treatment_NN
        outcome_NN ._.
        Studies_NNS have_VBP suggested_VBN that_IN tuberculosis_NNS and_CC HIV_NNP may_MD
        have_VB a_DT particularly_RB severe_JJ impact_NN on_IN young_JJ women_NNS in_IN a_DT
        low-income_JJ setting_NN [_NN 25_CD ]_NN ._. We_PRP did_VBD not_RB find_VB that_IN
        HIV-infected_NNP women_NNS fared_VBD any_DT worse_JJR from_IN tuberculosis_NNS than_IN
        men_NNS ._. Hudelson_NNP has_VBZ suggested_VBN that_IN delays_NNS in_IN care_NN seeking_VBG for_IN
        tuberculosis_NNS among_IN women_NNS may_MD be_VB compounded_VBN by_IN stigma_NN
        associated_VBN with_IN HIV_NNP infection_NN [_NN 25_CD ]_NN ._. We_PRP found_VBD no_DT gender_NN
        difference_NN in_IN the_DT duration_NN of_IN symptoms_NNS of_IN tuberculosis_NNS and_CC
        HIV_NNP prior_RB to_TO the_DT diagnosis_NN of_IN tuberculosis_NNS in_IN our_PRP$ study_NN
        cohort_NN ._.
        Differences_NNS in_IN compliance_NN with_IN anti-tuberculous_JJ
        chemotherapy_NN have_VBP been_VBN postulated_JJ to_TO exist_VB between_IN female_JJ
        and_CC male_JJ tuberculosis_NNS patients_NNS [_NN 26_CD ]_NN ._. Women_NNP have_VBP less_JJR
        access_NN to_TO funds_NNS for_IN transport_NN and_CC personal_JJ health-care_NN than_IN
        men_NNS do_VBP in_IN Africa_NNP ._. We_PRP were_VBD unable_JJ to_TO evaluate_VB compliance_NN
        because_IN all_DT patients_NNS were_VBD encouraged_VBN to_TO come_VB back_RB to_TO the_DT
        treatment_NN center_NN by_IN home_NN health-visitors_JJ and_CC those_DT who_WP
        defaulted_VBD on_IN their_PRP$ treatment_NN were_VBD often_RB brought_VBN to_TO the_DT
        clinic_NN ._.
        Biologically_NNP there_EX may_MD be_VB differences_NNS in_IN immune_JJ
        responses_NNS to_TO tuberculosis_NNS between_IN males_NNS and_CC females_NNS ._. It_PRP has_VBZ
        been_VBN suggested_VBN that_IN the_DT immune_JJ response_NN in_IN tuberculosis_NNS may_MD
        be_VB closely_RB related_VBN to_TO differences_NNS between_IN females_NNS and_CC males_NNS
        in_IN type_NN and_CC concentration_NN of_IN non-sex_JJ steroid_NN and_CC sex_NN
        steroid_NN hormones_NNS secreted_JJ [_NN 27_CD ]_NN ,_, the_DT direction_NN of_IN this_DT
        response_NN difference_NN is_VBZ ,_, however_RB ,_, unclear_JJ ._. Cell_NNP mediated_JJ
        immune_JJ responses_NNS are_VBP depressed_VBN by_IN protein-calorie_JJ
        malnutrition_NN [_NN 28_CD ]_NN ,_, and_CC this_DT could_MD account_VB for_IN
        differences_NNS in_IN the_DT response_NN to_TO tuberculosis_NNS in_IN males_NNS and_CC
        females_NNS since_IN females_NNS had_VBD significantly_RB lower_JJR body_NN mass_NN
        indices_NNS ._. However_RB ,_, females_NNS would_MD have_VB experienced_VBN more_RBR
        unfavorable_JJ outcomes_NNS than_IN males_NNS ,_, which_WDT is_VBZ not_RB what_WP we_PRP
        observed_VBD ._.
        This_DT study_NN is_VBZ subject_JJ to_TO at_IN least_JJS possible_JJ three_CD
        limitations_NNS :_: first_JJ ,_, the_DT relatively_RB small_JJ sample_NN size_NN ,_, could_MD
        have_VB contributed_VBN to_TO our_PRP$ inability_NN to_TO detect_VB clear_JJ gender_NN
        differences_NNS in_IN this_DT study_NN ._. To_TO detect_VB the_DT observed_VBN crude_NN
        relative_JJ risk_NN of_IN 1_CD ._. 02_CD given_VBN the_DT frequency_NN of_IN favorable_JJ
        outcomes_NNS at_IN one-year_JJ in_IN males_NNS of_IN 78_CD %_NN and_CC in_IN females_NNS of_IN 80_CD %_NN ,_,
        with_IN 95_CD %_NN confidence_NN and_CC 80_CD %_NN power_NN ,_, the_DT study_NN would_MD have_VB
        needed_VBN to_TO enroll_VB about_IN 9000_CD males_NNS and_CC 9300_CD females_NNS ._.
        However_RB ,_, the_DT modest_JJ gender_NN differences_NNS in_IN the_DT presentation_NN
        and_CC the_DT similarity_NN in_IN the_DT one-year_JJ outcome_NN that_IN this_DT study_NN
        suggests_VBZ could_MD provide_VB impetus_NN for_IN larger_JJR and_CC longer_JJR
        studies_NNS in_IN this_DT area_NN ,_, or_CC studies_NNS with_IN a_DT different_JJ design_NN
        e_SYM ._. g_SYM ._. ,_, case-control_JJ studies_NNS ._. Using_VBG the_DT repeated_VBN measures_NNS
        model_NN methodology_NN [_NN 20_CD 21_CD ]_NN allowed_VBD us_PRP to_TO use_VB more_JJR data_NNS
        points_NNS ,_, since_IN each_DT covariate_NN was_VBD updated_VBN at_IN the_DT different_JJ
        time_NN points_NNS ,_, and_CC it_PRP gave_VBD us_PRP more_JJR power_NN and_CC a_DT more_RBR robust_JJ
        estimation_NN of_IN the_DT effect_NN of_IN gender_NN on_IN outcome_NN than_IN using_VBG
        baseline_NN covariates_NNS would_MD have_VB done_VBN ._. The_DT second_JJ possible_JJ
        limitation_NN could_MD be_VB a_DT differential_NN follow-up_JJ rate_NN between_IN
        male_JJ and_CC female_JJ patients_NNS ,_, leading_VBG to_TO the_DT apparent_JJ trend_NN
        towards_IN better_JJR one-year_JJ outcomes_NNS in_IN the_DT female_JJ patients_NNS ._.
        Nonetheless_RB ,_, we_PRP do_VBP not_RB believe_VB that_IN there_EX was_VBD a_DT systematic_JJ
        difference_NN in_IN the_DT follow-up_JJ rate_NN by_IN gender_NN ,_, and_CC as_IN
        indicated_VBN ,_, home_NN health_NN visitors_NNS followed_VBN up_RP all_DT patients_NNS
        similarly_RB ._. The_DT third_JJ potential_JJ limitation_NN is_VBZ that_DT serum_NN β_NN 
        2_CD microglobulin_NN levels_NNS have_VBP not_RB been_VBN
        shown_VBN to_TO be_VB associated_VBN with_IN survival_NN in_IN HIV-infected_NNP
        patients_NNS on_IN antiretroviral_NN treatment_NN ,_, although_IN high_JJ levels_NNS
        generally_RB imply_VBP a_DT higher_JJR burden_NN of_IN HIV_NNP infection_NN ._. This_DT
        restricts_VBZ generalization_NN of_IN our_PRP$ results_NNS in_IN terms_NNS of_IN
        survival_NN ._.
      
      
        Conclusions_NNP
        We_PRP conclude_VBP that_IN female_JJ HIV-infected_NNP tuberculosis_NNS
        patients_NNS have_VBP a_DT similar_JJ one-year_JJ outcome_NN to_TO males_NNS in_IN
        Uganda_NNP ,_, even_RB though_IN they_PRP have_VBP lower_JJR body_NN mass_NN indices_NNS ,_,
        lower_JJR hemoglobin_NN levels_NNS ,_, and_CC higher_JJR β_NN 
        2_CD microglobulin_NN levels_NNS at_IN presentation_NN ,_,
        which_WDT may_MD indicate_VB more_JJR advanced_VBN HIV_NNP disease_NN than_IN the_DT
        males_NNS ._. Because_IN tuberculosis_NNS is_VBZ the_DT number_NN one_CD infectious_JJ
        disease_NN killer_NN of_IN women_NNS ,_, it_PRP is_VBZ imperative_JJ that_IN public_JJ
        health_NN workers_NNS in_IN areas_NNS of_IN high_JJ HIV_NNP and_CC tuberculosis_NNS
        prevalence_NN should_MD encourage_VB women_NNS to_TO present_VB for_IN screening_NN
        as_RB soon_RB as_IN they_PRP experience_VBP the_DT first_JJ signs_NNS of_IN
        tuberculosis_NNS ._.
      
      
        Competing_VBG interests_NNS
        We_PRP certify_VB that_IN we_PRP have_VBP participated_VBN sufficiently_RB in_IN the_DT
        conception_NN and_CC design_NN of_IN this_DT work_NN ,_, as_RB well_RB as_IN its_PRP$
        execution_NN and_CC the_DT analyses_NNS of_IN the_DT data_NNS ._. Further_RB we_PRP have_VBP
        collaboratively_RB written_VBN the_DT manuscript_NN and_CC take_VB public_JJ
        responsibility_NN for_IN it_PRP ._. We_PRP have_VBP reviewed_VBN the_DT final_JJ version_NN
        of_IN the_DT submitted_VBN manuscript_NN and_CC approve_VB it_PRP for_IN publication_NN ._.
        Neither_DT this_DT manuscript_NN nor_CC one_CD with_IN substantially_RB similar_JJ
        content_NN has_VBZ been_VBN published_VBN or_CC is_VBZ being_VBG published_VBN
        elsewhere_RB ._.
        We_PRP certify_VB that_IN we_PRP have_VBP no_DT affiliations_NNS with_IN or_CC
        involvement_NN in_IN any_DT organization_NN or_CC entity_NN with_IN a_DT direct_JJ
        financial_JJ interest_NN in_IN the_DT subject_JJ matter_NN or_CC materials_NNS
        discussed_VBN in_IN the_DT manuscript_NN ._. Dr_NNP ._. Nsubuga_NNP will_MD serve_VB as_IN the_DT
        corresponding_JJ author_NN ._.
        This_DT study_NN was_VBD funded_VBN by_IN a_DT grant_NN from_IN the_DT National_NNP
        Institutes_NNPS of_IN Health_NNP (_( AI_NNP 32414_CD )_) ._.
      
      
        List_NN of_IN abbreviations_NNS
        AIDS_NNP :_: Acquired_VBN Immune_NNP Deficiency_NNP Syndrome_NNP
        BMI_NNP :_: Body_NNP Mass_NNP Index_NNP
        HIV_NNP :_: Human_NNP immuno-deficiency_JJ virus_NN
      
    
  
